November and December have seen an abundance of new MAP publications by research groups affiliated with Human Para. Research by Otakaro Pathways, Dr. Saleh Naser, Dr. Marcel Behr, Dr. Leonardo Sechi, Dr. Horacio Bach and Dr. C. Thomas Dow are showcased in this update.
Make a difference for those with Crohn’s and other MAP-related conditions this holiday season! Giving Tuesday 2019 is fast approaching on December 3, 2019.
Human Para is raising funds for new MAP research projects. We have been working diligently with Children’s Hospital of Philadelphia, McGill University and Otakaro Pathways on a pilot testing study. As always, ALL funds raised on #GivingTuesday will go directly to MAP research. Please help us by supporting high quality MAP research this giving season.
Human Para’s inaugural MAP testing study is nearing completion. A total of 201 participants donated a blood sample at locations in Orlando, Philadelphia and New York City between May and September 2018. Blinded samples were sent to 6 research laboratories around the world, and MAP testing was completed by a variety of methods, including culture, PCR and antibody assays.
Read about our progress, a Phase 2 add on portion of the study currently being conducted, and when these results will be published!
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about mycobacteria, particularly Mycobacterium avium subsp. paratuberculosis (MAP), and the treatment of Crohn’s and immune disease with AMAT and other innovative therapies. Enjoy!
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about mycobacteria, particularly Mycobacterium avium subsp. paratuberculosis (MAP), and the treatment of Crohn’s and immune disease with AMAT and other innovative therapies. Enjoy!
Due to the recent success of RedHill Biopharma’s Stage 3 trial of RHB-104, more patients and doctors have become interested in Atypical Mycobacterial Antibiotic Therapy (AMAT) as a treatment option for chronic immune conditions, such as Crohn’s disease and multiple sclerosis. RHB-104 contains a triple combination of antibiotics that showed significant effectiveness in Crohn’s disease, and includes clarithromycin, Rifabutin and clofazimine. While clarithromycin and Rifabutin are easily available worldwide, clofazimine is not.
Read a first hand account from one man’s journey to legally obtain clofazimine for treatment of Crohn’s disease.